We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
Read MoreHide Full Article
Endocyte, Inc. incurred a loss of 18 cents per share in fourth-quarter 2017 wider than the Zacks Consensus Estimate of a loss of 16 cents. The figure was wider than the year-ago loss of 26 cents.
In September 2017, the company acquired exclusive worldwide rights to develop and commercialize PSMA-617 including the product candidate known as 177Lu-PSMA-617 from ABX GmbH. 177Lu-PSMA-617 is a first-in-class radioligand therapeutic (RLT) that targets prostate-specific membrane antigen (“PSMA”).
Over a year, Endocyte’s shares have rallied 97.6%, outperforming the industry’s gain of 0.4%.
Quarterly Details
Research and development (R&D) expenses declined 37.4% year over year to $5.2 million courtesy of the workforce reduction as part of the company’s restructuring plan, lower trial and manufacturing costs for EC1456, lower pre-clinical general research costs and a decrease in manufacturing expense for EC1169.
General and administrative expenses increased 19.8% year over year at $3.7 million due to higher legal and professional costs and an increase in compensation expense, including stock compensation expense.
During the quarter, the company finalized a phase III VISION trial design for177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA. The trial will include two interim assessments of efficacy, which could potentially lead to an early approval for 177Lu-PSMA-617. The VISION trial is a phase III study of 177Lu-PSMA-617 for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer, who have received at least one novel androgen axis drug and at least one taxane regimen. The primary endpoint of the study will be overall survival. Enrollment of the trial is expected to begin in second-quarter 2018 and is expected to be completed within 18-24 months.
Endocyte also entered into an agreement with ITM Isotopen Technologien München AG (“ITM”), a specialized radiopharmaceutical company, where the latter will provide clinical supply of no-carrier-added Lutetium for the manufacturing of 177Lu-PSMA-617.
In order to ensure the success of its VISION study, Endocyte added clinical trial professionals to the team. Caryn Barnett and Theresa Bruce both seasoned leaders with strong track records of executing late stage oncology development programs joined the company’s team.
Endocyte also finalized plans for the clinical development of adaptor-controlled CAR T-cell therapy in patients with osteosarcoma in fourth-quarter 2018.
2017 Results
For 2017, the company reported a loss of $1.25 per share wider than the loss of $1.04 in 2016. The loss is wider than the Zacks Consensus loss estimate of $1.24.
Regeneron’s earnings per share estimates have moved up from $17.13 to $18.65 and from $20.38 to $21.56 for 2018 and 2019 respectively in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Exelixis’ earnings per share estimates have moved up from 73 cents to 77 cents for 2018 in the last 60 days. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 572.92%. Share price of the company moved up 27.8% over a year.
Enanta Pharma delivered a positive earnings surprise in three of the last four quarters, with an average beat of 373.1%. Share price of the company surged 166.8% over a year
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
Endocyte, Inc. incurred a loss of 18 cents per share in fourth-quarter 2017 wider than the Zacks Consensus Estimate of a loss of 16 cents. The figure was wider than the year-ago loss of 26 cents.
In September 2017, the company acquired exclusive worldwide rights to develop and commercialize PSMA-617 including the product candidate known as 177Lu-PSMA-617 from ABX GmbH. 177Lu-PSMA-617 is a first-in-class radioligand therapeutic (RLT) that targets prostate-specific membrane antigen (“PSMA”).
Over a year, Endocyte’s shares have rallied 97.6%, outperforming the industry’s gain of 0.4%.
Quarterly Details
Research and development (R&D) expenses declined 37.4% year over year to $5.2 million courtesy of the workforce reduction as part of the company’s restructuring plan, lower trial and manufacturing costs for EC1456, lower pre-clinical general research costs and a decrease in manufacturing expense for EC1169.
General and administrative expenses increased 19.8% year over year at $3.7 million due to higher legal and professional costs and an increase in compensation expense, including stock compensation expense.
During the quarter, the company finalized a phase III VISION trial design for177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA. The trial will include two interim assessments of efficacy, which could potentially lead to an early approval for 177Lu-PSMA-617. The VISION trial is a phase III study of 177Lu-PSMA-617 for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer, who have received at least one novel androgen axis drug and at least one taxane regimen. The primary endpoint of the study will be overall survival. Enrollment of the trial is expected to begin in second-quarter 2018 and is expected to be completed within 18-24 months.
Endocyte also entered into an agreement with ITM Isotopen Technologien München AG (“ITM”), a specialized radiopharmaceutical company, where the latter will provide clinical supply of no-carrier-added Lutetium for the manufacturing of 177Lu-PSMA-617.
In order to ensure the success of its VISION study, Endocyte added clinical trial professionals to the team. Caryn Barnett and Theresa Bruce both seasoned leaders with strong track records of executing late stage oncology development programs joined the company’s team.
Endocyte also finalized plans for the clinical development of adaptor-controlled CAR T-cell therapy in patients with osteosarcoma in fourth-quarter 2018.
2017 Results
For 2017, the company reported a loss of $1.25 per share wider than the loss of $1.04 in 2016. The loss is wider than the Zacks Consensus loss estimate of $1.24.
Endocyte, Inc. Price, Consensus and EPS Surprise
Endocyte, Inc. Price, Consensus and EPS Surprise | Endocyte, Inc. Quote
Zacks Rank & Stocks to Consider
Endocyte carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the same space are Regeneron (REGN - Free Report) , Exelixis (EXEL - Free Report) and Enanta Pharma (ENTA - Free Report) . While Regeneronsports a Zacks Rank #1 (Strong Buy), Exelixis and Enanta Pharma carry a Zacks Rank #2 (Buy), each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $17.13 to $18.65 and from $20.38 to $21.56 for 2018 and 2019 respectively in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Exelixis’ earnings per share estimates have moved up from 73 cents to 77 cents for 2018 in the last 60 days. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 572.92%. Share price of the company moved up 27.8% over a year.
Enanta Pharma delivered a positive earnings surprise in three of the last four quarters, with an average beat of 373.1%. Share price of the company surged 166.8% over a year
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>